摘要
目的:探究大剂量二联疗法根除幽门螺杆菌(Hp)对肠道微生态的影响及相应益生菌干预效果。方法:选取纳入2023年10月~2024年4月龙岩市第一医院100例Hp感染者,以随机摸球法分为两组,各50例。对照组采用大剂量二联治疗,研究组采用大剂量二联联合益生菌治疗。比较两组Hp根除率、肠道微生态菌群情况、依从性、不良反应情况。结果:研究组Hp根除率稍高,但差异无统计学意义(P>0.05),治疗前,两组各项肠道微生态菌群比较,差异无统计学意义(P>0.05);治疗后,研究组肠球菌水平为(7.62±0.96)lgCFU/g,双歧杆菌水平为(8.67±0.98)lgCFU/g,乳杆菌水平为(8.57±0.62)lgCFU/g,肠杆菌水平为(6.98±0.86)lgCFU/g,各项水平均高于对照组,差异有统计学意义(t=2.593、4.956、8.861、2.156,P<0.05);研究组依从率较高,差异有统计学意义(P<0.05),不良反应比较,差异无统计学意义(P>0.05)。结论:大剂量二联疗法联用益生菌治疗Hp感染,可显著改善肠道微生态菌群情况,从而提高患者治疗依从性,且不良反应较低。
Objective To explore the effect of H.pylori eradication on intestinal microecology and the intervention effect of corresponding probiotics.Method 100 patients with H.pylori infection admitted to Longyan First Hospital from October 2023 to April 2024 were included,and they were divided into two groups with 50 cases each using random search method.The control group received high dose biplet and the study group received high dose biplet+probiotics.The Hp eradication rate,intestinal microecological flora,compliance,and adverse reactions were compared of two groups.Results The Hp eradication rate in the study group was higher,but the difference was not statistically significant(P>0.05),Before treatment,there was no statistically significant difference in the intestinal microecological flora between the two groups(P>0.05),After treatment,Enterococcus levels in the study group were(7.62±0.96)lgCFU/g,the level of bifidobacteria was(8.67±0.98)lgCFU/g,the level of L.lactis was(8.57±0.62)lgCFU/g,the level of enterobacteria was(6.98±0.86)lgCFU/g,All levels were higher than those in the control group,The difference showed statistical significance(t=2.593,4.956,8.861,2.156,P<0.05),the compliance rate of the research group was relatively high,and the difference was statistically significant(P<0.05),there was no statistically significant difference in adverse reactions compared(P>0.05).Conclusion Treatment of H.pylori infection with high-dose combination therapy can improve Hp eradication rate and improve intestinal microecological flora,thus improving treatment compliance with low adverse effects.
作者
林承春
刘奕明
钟平玉
黄淑敏
廖丽芳
LIN Cheng-Chun;LIU Yi-Ming;ZHONG Ping-Yu(Longyan First Hospital,Longyan 364000,Fujian,China)
出处
《吉林医学》
CAS
2024年第10期2447-2450,共4页
Jilin Medical Journal
基金
龙岩市科技计划项目[项目编号:2023LYF17047]。
关键词
大剂量二联疗法
幽门螺杆菌
肠道微生态
益生菌
依从性
HP根除率
High-dose binary therapy
Helicobacter pylori
Intestinal microecology
Probiotics
Compliance
Hp eradication rate